Dana Farber Cancer Institute, Boston, Massachusetts, United States
CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282
administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic
Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
H Lee Moffitt Cancer Center, Tampa, Florida, United States
CC-99282-NHL-001 study is a Phase I dose escalation and expansion clinical study of CC-99282
administered alone and in combination with rituximab in subjects with relapsed or refractory
non-hodgkin Lymphomas (R/R NHL).